Furthermore, several studies on darapladib, a drug that inhibits Lp-PLA2 activity, showed its beneficial effect on CVD in accordance with decreases in Lp-PLA2 activity; Mohler et al. [6] reported that darapladib dose-dependently decreased interleukin (IL)-6 in patients with stable coronary disease; Serruys et al. [7] indicated that its administration to patients with angiographically proven coronary disease inhibited the increase in necrotic core volume (coronary atheroma volume) compared to that of individuals who were not given the treatment. The gene discussed is IL6; the disease is coronary artery disorder.